{
    "nct_id": "NCT06540066",
    "official_title": "A Multicenter, Open-label, Phase 1a/1b Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B3227 as Monotherapy and in Combination With Tislelizumab in Patients With Advanced or Metastatic Solid Tumors",
    "inclusion_criteria": "* Histologically or cytologically confirmed locally advanced or metastatic solid tumors with a high prevalence of mucin-1 (MUC1) expression\n* At least 1 measurable lesion per RECIST v1.1\n* Stable Eastern Cooperative Oncology Group Performance Status of ≤ 1\n* Adequate organ function\n* Willing to use a highly effective method of birth control\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* History of prior ≥ Grade 3 Cytokine Release Syndrome (CRS)\n* History of severe Infusion-Related Reactions (IRRs), allergic reactions, or hypersensitivity to any ingredients or components of the study treatments\n* Infection requiring systemic (oral or intravenous) therapy ≤ 14 days before the first dose of study drug(s), or participants with symptomatic COVID-19 infection\n* Active leptomeningeal disease or uncontrolled, untreated brain metastasis\n* Active autoimmune disease or history of autoimmune disease(s) that may relapse\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply.",
    "miscellaneous_criteria": ""
}